• The pharma giant will lose its patent protection on semaglutide, which is sold as Ozempic and Wegovy, in Canada after not paying a nominal maintenance fee years before it became a blockbuster drug for fighting diabetes and obesity, Science reported. Novo Nordisk generates billions of dollars in revenue on the drug in Canada, but patent protection is due to end next year.

Years before semaglutide became a blockbuster drug for Novo Nordisk, the Danish pharma giant had a chance to maintain its patent in Canada but didn’t pay a small fee to do so, according to a recent report in Science.

The drug, which is sold as Ozempic and Wegovy, has made so much money for Novo Nordisk after exploding in popularity in the last few years that it has even impacted Denmark’s currency and interest rates.

To keep the semaglutide patent in Canada, the company had to pay an annual fee of just 250 Canadian dollars (~$185 USD). While it paid that amount in 2018, Science reported that it didn’t the following year.

The Canadian government offered Novo Nordisk another chance to keep its patent, this time with an additional charge that brought the total to 450 Canadian dollars ($331 USD).

“In order to prevent the patent from lapsing, the amount listed above, which includes the required maintenance fee and the late payment fee, must be paid within the one year period of grace following the filing date anniversary,” a letter from regulators said, putting the anniversary date at March 20, 2019. “Once a patent has lapsed it cannot be revived.”

Makers of generic drugs have taken notice, with Science pointing to recent comments from the company Sandoz that it has filed to launch a generic GLP-1 in Canada next year and expects approval sometime in the first quarter when exclusivity expires. 

“Interesting market. Novo never filed a patent in Canada. Never know why,” Sandoz CEO Richard Saynor told Endpoints News earlier this month. “I’m sure someone’s lost their job, but never mind. It’s the second-largest semaglutide market in the world.”

In a statement to Fortune, Novo Nordisk said there was no mistake regarding its patent maintenance fee in Canada and declined to comment on other drug manufacturers’ plans.

“All intellectual property decisions are carefully considered at a global level,” the company added. “Periods of exclusivity for pharmaceutical products end as part of their normal lifecycle and generic treatments may become available over time.”

The company confirmed that protection for semaglutide regulatory submissions in Canada will expire in 2026.

Meanwhile, Ozempic patents expire several years later in other big markets like the U.S. (2032), Japan (2031), and Europe (2031), according to the company’s most recent annual report.

Last year, Novo Nordisk generated about $19 billion in global Ozempic sales and about $9 billion in Wegovy sales. In Canada, retail pharmacies there booked Ozempic sales of 2.5 billion Canadian dollars.

This story was originally featured on Fortune.com

© Steve Christo—Corbis via Getty Images

A woman's human growth hormone treatments in childhood may have sealed her fate decades later, according to a new case report.

Two years ago, at a Stop & Shop in Rhode Island, the Danish neuroscientist and physician Henriette Edemann-Callesen visited an aisle stocked with sleep aids containing melatonin. She looked around in amazement. Then she took out her phone and snapped a photo to send to colleagues back home.

“It was really pretty astonishing,” she recalled recently.

In Denmark, as in many countries, the hormone melatonin is a prescription drug for treating sleep problems, mostly in adults. Doctors are supposed to prescribe it to children only if they have certain developmental disorders that make it difficult to sleep—and only after the family has tried other methods to address the problem.

Read full article

Comments

© kwanchaichaiudom via Getty

It's well-established that, on the whole, Americans die younger than people in most other high-income countries. For instance, an analysis from 2022 found that the average life expectancy of someone born in Switzerland or Spain in 2019 was 84 years. Meanwhile, the average US life expectancy was 78.8, lower than nearly all other high-income countries, including Canada's, which was 82.3 years. And this was before the pandemic, which only made things worse for the US.

Perhaps some Americans may think that this lower overall life-expectancy doesn't really apply to them if they're middle- or upper-class. After all, wealth inequality and health disparities are huge problems in the US. Those with more money simply have better access to health care and better health outcomes. Well-off Americans live longer, with lifespans on par with their peers in high-income countries, some may think.

It is true that money buys you a longer life in the US. In fact, the link between wealth and mortality may be stronger in the US than in any other high-income country. But, if you think American wealth will put life expectancy in league with Switzerland, you're dead wrong, according to a study in the latest issue of the New England Journal of Medicine.

Read full article

Comments

© Getty | Pascal Mora

A study released on Wednesday finds that a live-virus vaccine that limits shingles symptoms was associated with a drop in the risk for dementia when it was introduced. The work took advantage of the fact that the National Health Service Wales made the vaccine available with a very specific age limit, essentially creating two populations, vaccinated and unvaccinated, separated by a single date. And these populations showed a sharp divide in how often they were diagnosed with dementia, despite having little in the way of other differences in health issues or treatments.

What a day

This study didn't come out of nowhere. There have been a number of hints recently that members of the herpesvirus family that can infect nerve cells are associated with dementia. That group includes Varicella zoster, the virus that causes both chicken pox and—potentially many years after— shingles, an extremely painful rash. And over the past couple of years, observational studies have suggested that the vaccine against shingles may have a protective effect.

But it's extremely difficult to do a clinical trial given that the onset of dementia may happen decades after most people first receive the shingles vaccine. That's why the use of NHS Wales data was critical. When the first attenuated virus vaccine for shingles became available, it was offered to a subset of the Welsh population. Those who were born on or after September 2, 1933, were eligible to receive the vaccine. Anyone older than that was permanently ineligible.

Read full article

Comments

© Cavan Images